Imatinib failure-free survival (IFS) in patients with localized gastrointestinal stromal tumors (GIST) treated with adjuvant imatinib (IM): The EORTC/AGITG/FSG/GEIS/ISG randomized controlled phase III trial.
Paolo Giovanni Casali
Consultant or Advisory Role - Bayer; Novartis; Pfizer
Honoraria - Novartis; Pfizer
Research Funding - Bayer; Novartis; Pfizer
Other Remuneration - Novartis
Axel Le Cesne
Honoraria - Novartis; Pfizer
Research Funding - Novartis
Andres Poveda Velasco
Research Funding - Novartis
Dusan Kotasek
Research Funding - Novartis
Piotr Rutkowski
Consultant or Advisory Role - Novartis
Honoraria - Novartis; Pfizer
Peter Hohenberger
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis
Elena Fumagalli
Honoraria - Novartis
Research Funding - Novartis
Ian Robert Judson
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis
Antoine Italiano
Research Funding - Novartis; Pfizer
Javier Martin Broto
Consultant or Advisory Role - Novartis
Research Funding - Novartis
Alessandro Gronchi
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis
Other Remuneration - Novartis
Angelo Paolo Dei Tos
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis
Sandrine Marreaud
Research Funding - Novartis
Winette T.A. Van Der Graaf
Research Funding - Novartis
John Raymond Zalcberg
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis
Other Remuneration - Novartis
Saskia Litière
Research Funding - Novartis
Jean-Yves Blay
Consultant or Advisory Role - Novartis; Pfizer
Honoraria - Novartis; Pfizer
Research Funding - Novartis; Pfizer